With the increase in number of fully vaccinated population and the trend of moving from pandemic to endemic worldwide, there is a shift of focus on use of SARS-CoV-2 serology assays for diagnosing past infections to evaluating vaccine-induced immune protection. Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs protect the host from viral infection by binding to sites on the virus and inhibiting entry of the virus into the host cell.
In this session, Dr. Su Chengxun will discuss challenges in COVID-19 post-vaccination monitoring, protection against new variant of concerns, as well as limitations of existing serology methods. We will also review cPass™ correlate of protection, NAb longevity in infected & vaccinated individuals, its importance in next-generation vaccine development and why cPass™ can potentially guide booster shot regimen and serve as COVID-19 ‘exit strategy’ to reopen the economy and society.